Author Archives: admin


Stem Cell Clinic > Articles by: admin

AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell…

By Stell Cell Research

CAMBRIDGE, Mass & HOUSTON--(BUSINESS WIRE)-- AlloVir, a late-clinical stage T-cell immunotherapy company, today announced the expansion of its research and development collaboration with Baylor College of Medicine to include the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies to combat SARS-CoV-2, the virus that causes COVID-19. With AlloVirs proprietary technology, in addition to targeting SARS-CoV-2, the investigational virus specific T-cell therapy may also address other coronavirus (CoV) strains including SARS-CoV, MERS-CoV, and also the endemic CoVs that commonly afflict immunocompromised patients. AlloVir aims to develop a therapy for CoVs that can be used as a stand-alone treatment or incorporated into the companys multi-respiratory virus investigational therapy, ALVR106, which is designed to address other devastating and life-threatening community-acquired respiratory viruses.

Given the worldwide coronavirus pandemic and risks to immunocompromised patients now and in the future, we believe it is our responsibility to leverage our scientific expertise and allocate resources for an allogeneic, off-the-shelf, coronavirus-specific T-cell program, said Ann Leen, Ph.D., AlloVir Co-Founder, Chief Scientific Officer, and Professor of Pediatrics at Baylor College of Medicine. Together with Baylor College of Medicine we have already advanced two highly innovative allogeneic, off-the-shelf, multi-virus specific T-cell investigational immunotherapies. We believe we can apply this same approach to develop a cell therapy to treat and prevent coronavirus infections and diseases in immunocompromised patients.

AlloVir and Baylor College of Medicine are leading the way in the clinical development of novel immunotherapies designed to restore natural T-cell immunity to fight off viral infections and diseases in immunocompromised patients, including recipients of stem cell and solid organ transplants, said Michael Dilling, Executive Director of Baylor Licensing Group within Baylor College of Medicine Ventures. Expanding upon this collaboration and technology platform to treat and possibly prevent other emerging life-threatening community-acquired virus infections and diseases is a natural extension of our partnership.

About AlloVirs Approach:

T cells are vital to the immune systems ability to detect and kill virus-infected cells. In healthy individuals, virus-specific T cells form a critical component of the bodys natural defense system and provide protection against thousands of disease-causing viruses.

However, these viruses can go unchecked in immunocompromised patients, such as those undergoing hematopoietic stem cell transplantation (HSCT), solid organ transplantation, and cancer treatment; in patients with HIV infection; and in the elderly. Typically, when viruses attack immunocompromised patients, standard of care therapies do not address the underlying problem of a weakened immune system and, therefore, many patients suffer with life-threatening outcomes such as multi-organ damage and failure, and even death.

AlloVir uses natural immune stimulant proteins called cytokines combined with non-harmful fragments of the virus to activate and expand naturally occurring cells against target viruses. These cells are then provided to immunocompromised patients in order to restore natural T-cell immunity to prevent and/or treat associated viral infections and diseases. AlloVir has developed a proprietary manufacturing process that allows for a bank of virus-specific T cells to be developed from a small number of carefully chosen, healthy, virus-immune, third-party donors. AlloVirs virus-specific T-cells therapies do not require exact immunological matching to patients, allowing hundreds of patients to be treated with virus-specific T-cells manufactured from a single donor. AlloVirs therapies can be stored in a frozen state and thus supplied rapidly and globally as an off-the-shelf therapy for patients suffering from, or at risk for, one or more viral infections and diseases.

About AlloVir

AlloVir, formerly ViraCyte, is an ElevateBio portfolio company that was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The companys technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVirs technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

AlloVirs lead product Viralym-M (ALVR105) is in late-stage clinical development as an allogeneic, off-the-shelf, multi-virus specific T-cell therapy targeting six common viral pathogens in immunocompromised individuals: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. In a positive Phase 2 proof-of-concept study, published in the Journal of Clinical Oncology (Tzannou, JCO, 2017), greater than 90% of patients who failed conventional treatment and received the companys lead allogeneic T-cell therapy, Viralym-M, demonstrated a predefined criteria for a complete or partial clinical response, most with complete elimination of detectable virus in the blood and resolution of major clinical symptoms. The company plans to initiate pivotal and proof-of-concept studies with Viralym-M in 2020 for treatment and prevention of severe and life-threatening viral infections and diseases.

AlloVirs second allogeneic, off-the-shelf, multi-virus specific T-cell therapy, ALVR106, targets four common and devastating community-acquired respiratory viruses: respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus (Vasileiou, Haematologica, 2019). The company anticipates initiating clinical studies with ALVR106 in 2020.

AlloVirs investors include Fidelity Research and Management Company, Gilead Sciences, F2 Ventures, The Invus Group, Redmile Group, EcoR1, Samsara Biocapital, and Leerink Partners Co-investment Fund, LLC.

For more information visit http://www.allovir.com

About ElevateBio

ElevateBio, LLC, is a Cambridge-based biotechnology company, established to create and operate a broad portfolio of cell and gene therapy companies with leading academic researchers, medical centers and entrepreneurs. ElevateBio builds companies by providing scientific founders with fully integrated bench-to-bedside capabilities including world-class scientists, manufacturing facilities, drug developers and commercial expertise. ElevateBio BaseCamp, a company-owned Cell and Gene Therapy Center of Innovation, will serve as the R&D, process development and manufacturing hub across the entire ElevateBio portfolio while also supporting selected strategic partners. For more information, visit http://www.elevate.bio.

About Baylor College of Medicine

Baylor College of Medicine (www.bcm.edu) in Houston is recognized as a health sciences university and is known for excellence in education, research and patient care. It is the only private medical school in the greater southwest and is ranked 22nd among medical schools for research and 4th for primary care by U.S. News & World Report. Baylor is listed 20th among all U.S. medical schools for National Institutes of Health funding and No. 1 in Texas. Located in the Texas Medical Center, Baylor has affiliations with seven teaching hospitals and jointly owns and operates Baylor St. Lukes Medical Center, part of CHI St. Lukes Health. Currently, Baylor has more than 3,000 trainees in medical, graduate, nurse anesthesia, physician assistant, orthotics and genetic counseling as well as residents and postdoctoral fellows. Follow Baylor College of Medicine on Facebook (http://www.facebook.com/BaylorCollegeOfMedicine) and Twitter (http://twitter.com/BCMHouston).

View source version on businesswire.com: https://www.businesswire.com/news/home/20200323005168/en/

Original post:
AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell...

eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine for High Risk Populations – BioSpace

By Stell Cell Research

NIEL, Belgium, March 24, 2020 /PRNewswire/ -- eTheRNA Immunotherapies nv ('eTheRNA' or 'The Company'), a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform, today announced that a consortium has been formed with North American and European partners to develop a novel mRNA vaccine against CoV-2 and preclinical development has started. Chinese partners may be added in the consortium in due course.

Administered intranasally, the proposed vaccine is intended primarily for high risk populations such as healthcare workers and families of confirmed cases. It is also designed to be protective against future variations of the virus by targeting conserved epitopes from the whole CoV-2 genome. eTheRNA and its partners EpiVax, Nexelis, REPROCELL and CEV* have extensive experience in the mRNA vaccine field and this will help accelerate progress towards clinical trials with patient enrolment expected in early 2021.

Steven Powell, eTheRNA's CEO, explained the aims of the consortium: "Viral variation means traditional medicinal and preventive vaccine approaches may fall short when confronted with seasonal or outbreak situations. A vaccine to defend against current and future outbreaks of coronavirus and other respiratory viral pathogens should be robust against viral genome changes, provide a platform that enables rapid introduction of a new viral target, be easy and safe to administer and be scaleable and suitable for stockpiling. The innovative vaccine program we have started with our partners incorporates all of these essential features."

Traditional vaccines are based on generating an antibody response to outer surface viral protein targets. However, viral variation may greatly reduce the effectiveness of this approach. For example, the SARS-CoV-2 outer surface spike protein (S) is less than 40% homologous to SARS-CoV-1. Furthermore, it has also been reported in several cases that vaccines with suboptimal antibody response (too low or not neutralizing) have facilitated viral entry and been linked to disease enhancement.

The eTheRNA consortium's approach selects conserved epitopes from the whole viral genome. Creating a vaccine that mounts a strong cellular (T cell) based response against these epitopes offers a better chance to overcome viral variability. Intranasal delivery has been chosen since the mucosa of the upper respiratory tract are the immune system's primary line of defense. A strong nasal T cell effector and memory response is claimed to fight viral replication, colonization of the lung and thus disease. mRNA has also been demonstrated to induce strong T cell responses by intranasal delivery.

The development programme has been initiated and is focused on a vaccine candidate that integrates 3 different technologies:

"While valuable initiatives and strong support are being deployed into the development of medicinal and vaccine solutions for immediate use against SARS-CoV-2, it is also important that development of solutions for the longer term should also start as soon as possible," concluded Powell. "Our target is to bring this into clinical testing in early 2021."

Information for editors

About eTheRNA immunotherapies

eTheRNA immunotherapies is a clinical-stage company developing innovative immunotherapies from its proprietary mRNA TriMix platform. eTheRNA was established in January 2013 as a spin-off from the VUB university in Belgium and is developing products for the treatment of cancer and infectious disease.

About TriMix

The TriMix platform, on which eTheRNA's immunotherapies are based, comprises three mRNAs encoding proteins (caTLR4, CD40L and CD70) that work to deliver optimal activation of dendritic cells. These cells behave as immune response mediators and mobilize the immune system to attack cancer cells through inducing a T-cell response. Clinical proof of concept for TriMix-based immunotherapies has been established through an extensive dataset demonstrating clinical benefits in advanced melanoma patients.

About EpiVax

EpiVax is a 21-year old privately held biotechnology company located in Providence, Rhode Island. Scientists at EpiVax, led by co-founders Annie De Groot, MD and Bill Martin, lead in the fields of immunogenicity risk assessment and computational vaccinology with expertise in T cell epitope prediction, immune modulation, and rapid vaccine design. EpiVax's broad portfolio of projects includes vaccines and immunotherapies for infectious diseases, autoimmunity and cancer. EpiVax's proprietary in silico immunogenicity screening toolkits for therapeutics and vaccines, ISPRI and iVAX, are employed in advancing the research of a global roster of companies. Visit http://www.epivax.com for more information.

About Nexelis

With unrivaled expertise in immunology on both sides of the client/CRO relationship, and operating sites in North America (East and West Coast) and Europe, Nexelis is a leading provider of assay development and advanced laboratory testing services in the infectious diseases, metabolic diseases, and oncology fields. Our versatile team of scientists, working with our advanced technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 100 new molecular entities, including blockbuster vaccines, anti-viral drugs, and immunotherapy, gene and cell therapy products. Visit http://www.nexelis.com for more information.

About REPROCELL

REPROCELL was established in 2003 to accelerate medical research via cutting-edge stem cell and human tissue-based technologies, including the use of novel transfection reagents and RNA-based methods for the generation of induced pluripotent stem cells. REPROCELL has further diversified its portfolio of products and services to include predictive drug discovery services in human fresh tissues, technologies for the manufacture of bioengineered human tissues, industry-leading gene editing technology and one of the largest commercial repositories of ethically sourced human tissue. Visit http://www.reprocell.com for more information.

About CEV

The Centre for the Evaluation of Vaccination (CEV) of the University of Antwerp, headed by Prof. Pierre Van Damme, is a clinical trial centre specialized in the conduct of vaccine trials. It has performed Phase I until Phase IV clinical trials in all age groups. The CEV is internationally known for its professional and qualitative vaccine clinical trial facility and organisation and is therefore a regular partner in vaccine clinical trials, i.e. for EU funded clinical trials, for investigator-driven vaccine trials as well as for industry funded clinical trials. For more information visit https://www.uantwerpen.be/en/research-groups/centre-for-evaluation-vaccination/

Contact information

media@etherna.be

Or

Richard HayhurstRHAprMobile +44 (0)7711-821-527richard@rhapr.eu

View original content:http://www.prnewswire.com/news-releases/etherna-launches-an-international-consortium-and-starts-development-of-cross-strain-protective-cov-2-mrna-vaccine-for-high-risk-populations-301028630.html

SOURCE eTheRNA

Excerpt from:
eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine for High Risk Populations - BioSpace

Triangle headliners: Roundup of events (most of them virtual) through March 31 – WRAL Tech Wire

By Stell Cell Research

WRAL TechWire keeps tabs on the latest and greatest meetups, panels, workshops, conferences, application deadlines and all things happening in the North Carolina startup/tech world.The Headliners is a multi-part weekly roundup of upcoming events to add to your calendar. Below is a list of March events in Raleigh, Durham, Chapel Hill and the greater Triangle area. To find out whats happening this month in cities outside of the Triangle, check out part two of the Headliners column. Another post highlights events in April. Meetups that occur regularly are listed here.

If youd like your event to be included, feel free to send me an email.

Also, check out a full range of events on TechWires interactive calendar, along with our comprehensive resource guide for startups in the Triangle.

Last week, we kept a running list of canceled or postponed events due to coronavirus concerns. Check it for last weeks updates. The following list is our lineup of Triangle events through the end of Marchmost have been switched to a virtual format in light of social distancing recommendations.

This monthly webinar series hosts a global health professional who will share insights and advice for advancing your career. This months webinar features Kimberly Thigpen Tart of the National Institute for Environmental Health Sciences.

In this virtual session, IT leaders at NC TECH member companies will discuss relevant topics and best practices in their field. Brighthouse Financial CIO Jeff Hughes will facilitate the discussion.

This online meeting convenes CISOs, VPs and director-level security leaders from NC TECH member companies. A roundtable discussion will be facilitated by Bill Dupre, director of security at Railinc Corp.

Leadership Raleigh is a leadership development program run by the Raleigh Chamber of Commerce. Applications for the next cohort are due on May 8. Join this information session to hear from Leadership Raleigh alumni about their experience.

The Ladies That UX Durham meetup is hosting a virtual lunch where the community can network and discuss UX topics.

Join the Code for Chapel Hill meetup to network with like-minded individuals and work on civic hacking projects. Meetings are held every two weeks on Tuesdays.

1 Million Cups, presented by Kauffman, is a weekly informal pitch event for the startup community. Join for free coffee and entrepreneurial support as local startups deliver their presentations.

In this webinar, StrongKey COO Jake Kise will outline the top preventative measures for protecting your businesss data as teams transition to remote work amid the coronavirus pandemic.

RTI Innovation Advisors is hosting a webinar with tips and best practices on designing virtual workshops, hosting online collaboration sessions and using virtual tools to manage projects.

NC IDEA LABS is a four-week customer discovery program that helps idea-stage entrepreneurs take their first steps toward building a successful startup. The next cohort will run from May 26 to June 19, and applications are due on April 15. Attend this webinar to learn more about the program and how to write a competitive application.

This month, LaunchBios Larger Than Life Science event (usually held in Durham) is going virtual, allowing life science entrepreneurs from anywhere in the world to join and hear from experts discussing regenerative medicine and stem cell research. More TechWire coverage here.

Join Startup Summit to hear from Barfield Revenue Consulting Founder and CEO Will Barfield on startup recruiting.

This 14-week summer accelerator provides NC State entrepreneurs with funding, resources and guidance to build their startups.

This free bi-monthly event offers a space for local tech professionals to build connections and find potential job opportunities.

This weekly meetup brings together developers, IT professionals and tech enthusiasts who are interested in the Google Cloud Platform.

The 12-week RIoT Accelerator Program connects early-stage IoT startups with an industry consortium of more than 80 companies to learn, partner and bring your product to market. The summer 2020 cohort will run from May 26 to August 14 in Raleigh.

UNCs CUBE program involves one year of specialized programming with one-on-one coaching, connecting with a network of social entrepreneurs and venture development resources. Note: Applications have been extended to March 30.

Bring your ideas and opinions to the next Midtown Techies meetup. Events are held on the last Tuesday of every month.

Read more:
Triangle headliners: Roundup of events (most of them virtual) through March 31 - WRAL Tech Wire

Stem Cell Therapy Market 2020 : Top Countries Data, Industry Size, Growth Factors, Defination, Global Analysis, Opportunities And Forecast To 2026 -…

By Stell Cell Research

Global Stem Cell Therapy Market 2020 Research Report provides key analysis on the market status of the Stem Cell Therapy manufacturers with best facts and figures, meaning, definition, SWOT analysis, expert opinions and the latest developments across the globe. The Report also calculate the market size, Stem Cell Therapy Sales, Price, Revenue, Gross Margin and Market Share, cost structure and growth rate. The report considers the revenue generated from the sales of This Report and technologies by various application segments.

Final Report will add the analysis of the impact of COVID-19 on this Stem Cell Therapy industry.

The objective of the study is to define market sizes of different segments and countries in previous years and to forecast the values to the next Five years. The report is designed to incorporate both qualify qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as drivers and restraining factors which will define the future growth of the Stem Cell Therapy market.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/15067862

The research covers the current Stem Cell Therapy market size of the market and its growth rates based on 6-year records with company outline of Key players/manufacturers:

Short Description about Stem Cell Therapy Market:

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

In the last several years, global stem cell therapy market developed fast at a average growth rate of 46.81%.

Scope of the Stem Cell Therapy Market Report :

In 2019, The Global Stem Cell Therapy market size was USD 403.6 million and it is expected to reach USD 1439.9 million by the end of 2026, with a CAGR of 19.7% during 2021-2026.

This report focuses on the Stem Cell Therapy in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Get a Sample Copy of the Stem Cell Therapy Market Report 2020

Report further studies the market development status and future Stem Cell Therapy Market trend across the world. Also, it splits Stem Cell Therapy market Segmentation by Type and by Applications to fully and deeply research and reveal market profile and prospects.

Major Classifications are as follows:

Major Applications are as follows:

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Stem Cell Therapy in these regions, from 2015 to 2026, covering

This Stem Cell Therapy Market Research/Analysis Report Contains Answers to your following Questions

Inquire more and share questions if any before the purchase on this report at https://www.360researchreports.com/enquiry/pre-order-enquiry/15067862

Major Points from Table of Contents:

Global Stem Cell Therapy Market Research Report 2020-2026, by Manufacturers, Regions, Types and Applications

1 Study Coverage1.1 Stem Cell Therapy Product1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered1.4 Market by Type1.4.1 Global Stem Cell Therapy Market Size Growth Rate by Type1.5 Market by Application1.5.1 Global Stem Cell Therapy Market Size Growth Rate by Application1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Stem Cell Therapy Production2.1.1 Global Stem Cell Therapy Revenue 2015-20262.1.2 Global Stem Cell Therapy Production 2015-20262.1.3 Global Stem Cell Therapy Capacity 2015-20262.1.4 Global Stem Cell Therapy Marketing Pricing and Trends2.2 Stem Cell Therapy Growth Rate (CAGR) 2020-20262.3 Analysis of Competitive Landscape2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)2.3.2 Key Stem Cell Therapy Manufacturers2.4 Market Drivers, Trends and Issues2.5 Macroscopic Indicator2.5.1 GDP for Major Regions2.5.2 Price of Raw Materials in Dollars: Evolution

3 Market Size by Manufacturers3.1 Stem Cell Therapy Production by Manufacturers3.1.1 Stem Cell Therapy Production by Manufacturers3.1.2 Stem Cell Therapy Production Market Share by Manufacturers3.2 Stem Cell Therapy Revenue by Manufacturers3.2.1 Stem Cell Therapy Revenue by Manufacturers (2015-2020)3.2.2 Stem Cell Therapy Revenue Share by Manufacturers (2015-2020)3.3 Stem Cell Therapy Price by Manufacturers3.4 Mergers and Acquisitions, Expansion Plans

4 Stem Cell Therapy Production by Regions4.1 Global Stem Cell Therapy Production by Regions4.1.1 Global Stem Cell Therapy Production Market Share by Regions4.1.2 Global Stem Cell Therapy Revenue Market Share by Regions4.2 United States4.2.1 United States Stem Cell Therapy Production4.2.2 United States Stem Cell Therapy Revenue4.2.3 Key Players in United States4.2.4 United States Stem Cell Therapy Import and Export4.3 Europe4.3.1 Europe Stem Cell Therapy Production4.3.2 Europe Stem Cell Therapy Revenue4.3.3 Key Players in Europe4.3.4 Europe Stem Cell Therapy Import and Export4.4 China4.4.1 China Stem Cell Therapy Production4.4.2 China Stem Cell Therapy Revenue4.4.3 Key Players in China4.4.4 China Stem Cell Therapy Import and Export4.5 Japan4.5.1 Japan Stem Cell Therapy Production4.5.2 Japan Stem Cell Therapy Revenue4.5.3 Key Players in Japan4.5.4 Japan Stem Cell Therapy Import and Export4.6 Other Regions4.6.1 South Korea4.6.2 India4.6.3 Southeast Asia

5 Stem Cell Therapy Consumption by Regions5.1 Global Stem Cell Therapy Consumption by Regions5.1.1 Global Stem Cell Therapy Consumption by Regions5.1.2 Global Stem Cell Therapy Consumption Market Share by Regions5.2 North America5.2.1 North America Stem Cell Therapy Consumption by Application5.2.2 North America Stem Cell Therapy Consumption by Countries5.2.3 United States5.2.4 Canada5.2.5 Mexico5.3 Europe5.3.1 Europe Stem Cell Therapy Consumption by Application5.3.2 Europe Stem Cell Therapy Consumption by Countries5.3.3 Germany5.3.4 France5.3.5 UK5.3.6 Italy5.3.7 Russia5.4 Asia Pacific5.4.1 Asia Pacific Stem Cell Therapy Consumption by Application5.4.2 Asia Pacific Stem Cell Therapy Consumption by Countries5.4.3 China5.4.4 Japan5.4.5 South Korea5.4.6 India5.4.7 Australia5.4.8 Indonesia5.4.9 Thailand5.4.10 Malaysia5.4.11 Philippines5.4.12 Vietnam5.5 Central and South America5.5.1 Central and South America Stem Cell Therapy Consumption by Application5.5.2 Central and South America Stem Cell Therapy Consumption by Countries5.5.3 Brazil5.6 Middle East and Africa5.6.1 Middle East and Africa Stem Cell Therapy Consumption by Application5.6.2 Middle East and Africa Stem Cell Therapy Consumption by Countries5.6.3 Turkey5.6.4 GCC Countries5.6.5 Egypt5.6.6 South Africa

6 Market Size by Type6.1 Global Stem Cell Therapy Breakdown Dada by Type6.2 Global Stem Cell Therapy Revenue by Type6.3 Stem Cell Therapy Price by Type

7 Market Size by Application7.1 Overview7.2 Global Stem Cell Therapy Breakdown Dada by Application7.2.1 Global Stem Cell Therapy Consumption by Application7.2.2 Global Stem Cell Therapy Consumption Market Share by Application (2015-2020)

Continued.

Purchase this report (Price 3900 USD for a single-user license) https://www.360researchreports.com/purchase/15067862

About Us:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us:Name: Mr. Ajay MoreEmail: [emailprotected]Organization: 360 Research ReportsPhone: +44 20 3239 8187/ +14242530807

For More Related Reports Click Here :

Weatherstrip Seal Market 2020 : Top Countries Data, Growth Factors, Defination, Business Opportunity, Trend, Segmentation and Forecast to 2026

Organic Soy Lecithin Market Size 2020 : Top Countries Data, Defination, Business Opportunity, SWOT Analysis, Applications, Trends and Forecast to 2026

Bottle Sealing Wax Market Size 2020 : Top Countries Data, Defination, Business Opportunity, SWOT Analysis, Applications, Trends and Forecast to 2026

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Stem Cell Therapy Market 2020 : Top Countries Data, Industry Size, Growth Factors, Defination, Global Analysis, Opportunities And Forecast To 2026

See the original post here:
Stem Cell Therapy Market 2020 : Top Countries Data, Industry Size, Growth Factors, Defination, Global Analysis, Opportunities And Forecast To 2026 -...

Mustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights – Yahoo Finance

By Stem Cell Medicine

NEW YORK, March 16, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the full year ended December 31, 2019.

Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, We are delighted by Mustangs numerous accomplishments in 2019. We started off the year by executing a worldwide license agreement with Nationwide Childrens Hospital to develop MB-108, oncolytic virus C134, for the treatment of glioblastoma multiforme. In April, we announced the exciting New England Journal of Medicine publication of positive Phase 1/2 data from our partner, St. Jude Childrens Research Hospital (St. Jude), which demonstrated the curative potential of MB-107, a lentiviral gene therapy for X-linked severe combined immunodeficiency (XSCID), also known as bubble boy disease. We plan to transfer the MB-107 Investigational New Drug (IND) application from St. Jude to Mustang shortly. In August, the FDA accepted our first IND application to initiate a multi-center Phase 1/2 clinical trial of MB-102 (CD123-targeted CAR T cell therapy) in acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk myelodysplastic syndrome. We look forward to dosing our first patient soon, using MB-102 processed at our own cell processing facility.

Dr. Litchman continued, In 2019, we were also pleased that the FDA granted prestigious designations to our drug candidates, including the Regenerative Medicine Advanced Therapy (RMAT) designation to MB-107 and Orphan Drug Designations to MB-108 for the treatment of malignant glioma and to MB-102 for the treatment of AML. In addition, several Phase 1 trials were initiated with our collaborators during the year, including the MB-104 (CS1-targeted CAR T cell therapy) trial at City of Hope for multiple myeloma, the MB-105 (PSCAtargeted CAR T cell therapy) trial at City of Hope for the treatment of prostate cancer, the MB-103 (HER2-targeted CAR T cell therapy) trial at City of Hope for the treatment of glioblastoma multiforme and of HER2-positive breast cancer with brain metastases, the MB-101 (IL13R2-targeted CAR T cell therapy) trial at City of Hope in combination with checkpoint inhibitors for the treatment of recurrent malignant glioma, and the MB-108, oncolytic virus C134, trial for the treatment of glioblastoma multiforme at the University of Alabama at Birmingham.

Dr. Litchman concluded, Mustang raised a total of $69 million throughout 2019, which enables us to continue to advance our gene and CAR T cell therapy programs. We look forward to maintaining this positive momentum through 2020, including several important data readouts anticipated in the second half of the year.

Financial Results:

2019 and Recent Corporate Highlights:

About Mustang BioMustang Bio, Inc. (Mustang) is a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission. Mustang was founded by Fortress Biotech, Inc. (FBIO). For more information, visit http://www.mustangbio.com.

ForwardLooking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on managements current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Story continues

Company Contacts:Jaclyn Jaffe and William BegienMustang Bio, Inc.(781) 652-4500ir@mustangbio.com

Investor Relations Contact:Daniel FerryLifeSci Advisors, LLC(617) 430-7576daniel@lifesciadvisors.com

Media Relations Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com

Originally posted here:
Mustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights - Yahoo Finance

The American Academy of Stem Cell Physicians Recommends a Treatment Protocol for COVID-19 to the WHO – Yahoo Finance

By Stem Cell Doctors

Treatment plans are outlined for doctors and hospitals by The American Academy of Stem Cell Physicians

MIAMI, March 19, 2020 /PRNewswire/ --The American Academy of Stem Cell Physicians has Recommendations for the Treatment of COVID-19. Treatment plans were sent to the WHO representatives and DirectorDr. Tedros Adhanom earlier today.

The following are recommendations of The American Academy of Stem Cell Physicians for treatment of COVID-19:

For Hospitalized Patients (Based on 70KG weight):

1. Intravenous Vitamin C 50 grams QD (Need to check patients for G6PD deficiency before high dose IVC.)2. Zinc 8mg IV QD3. Vitamin D3 100000-150000 IU Intramuscularly QD4. Chloroquine 10mg/kg bid5. Umbilical Cord Blood - 1 million MNC/kg QD6. Nebulizer with Amniotic fluid derived Exosomes 1 Billion/Kg Q4h.

Please note the vitamins and minerals are given at a higher dose than are normally recommended and physicians should do prophylaxis for gastrointestinal protection and add probiotics.

Non-Hospitalized Patients:

1. Zinc 40 mg BID2. Vitamin C 5000mg/day3. Chloroquine 500mg BID initial loading dose of 1000mg4. Vitamin D 5000 IU QD5. Oral iodine 300mg PO bid

6. Dietary and lifestyle recommendations:a. 8oz of water/hourb. No sugarc. More vegetables at each meal.d. Exercise 30 minutes per day.e. Meditate.f. Sleep minimum of 7-8 hours/day.

A spokesman for The American Academy of Stem Cell Physicians, Dr. A.J. Farshchian said earlier today,"The AASCP members have been working on the above protocol this past week. We have to thank all the physicians contributing to this protocol in particular."

Thephysicians are :

Kristine Salter, M.D.Sunny Kim, M.D.Pedro Abrantes, DPMTom Yarema, M.D.Robert Hamilton, M.D.

This protocol is to be tailored for each individual patient. Physicians from around the world are welcome to contact us, as we will continuously be updating this protocol.

For updates, check The American Academy of Stem Cell Physicians website: http://www.aascp.net.

About AASCP

The American Academy of Stem Cell Physicians (AASCP) is an organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatment, and prevention of disease related to or occurring within the human body. The AASCP aims to serve as an educational resource for physicians, scientists, and the public.

Contact Marie Barba at AASCP.net or305-891-4686.

Related Images

aascp-recommendations-to-treat.jpeg AASCP recommendations to treat Covid-19 AASCP recommendation memo

View original content:http://www.prnewswire.com/news-releases/the-american-academy-of-stem-cell-physicians-recommends-a-treatment-protocol-for-covid-19-to-the-who-301026685.html

SOURCE The American Academy of Stem Cell Physicians

Read the rest here:
The American Academy of Stem Cell Physicians Recommends a Treatment Protocol for COVID-19 to the WHO - Yahoo Finance

March 21: 7 best things that happened this week – The Vanderbilt Hustler

By Stem Cell Doctors

Whether youre feeling anxious, stressed, fearful or straight bored, everyones emotions were running high this week. But believe it or not, some (shocker!) actually great things happened while we were drowning in the headlines. Read on for the seven best things that happened over the last seven days.

MAttigan Kelly

While the world feels like it's falling apart, at least people are fostering more puppies! Read on for other great things that happened this week.

1. Britney Spears made a stand for herself and, well, everyone.

Contrary to popular belief, Britney is very much still in. If you dont follow her Instagram, do yourself a favor, follow it and prepare for your feed to be flooded with her washboard abs and clich screenshots of quotes thatll bring you back to 2012. At 38 and with 2 kids, I can only hope to look like Britney when I grow up. With that being said, she receives her fair share of hate on social media for her Ill post whatever I want attitude and stream of bikini shots. On Wednesday, the Queen of Pop had had enough. She clapped back on all her haters with a genuine post (featuring yet another screenshotted quote) advocating for her right to basically do what she wants and post what she wants without having to deal with online bullies. Especially in todays climate of fear and anxiety, Britney shouldnt have to deal with strangers telling her what to post, and neither should we.

2. The second patient ever was cured of HIV in London.

While everyones busy worrying about not contracting COVID-19, a medical breakthrough happened on March 10 in London. Fourty-year-old Adam Castillejo had been taking HIV medication for months, but it was not that which cured him. Doctors say a stem cell treatment that he received for cancer involved an uncommon gene which stopped the virus from replicating in his body. It is now a year after he was announced clear of the virus, which researcher Prof. Ravindra Kumar Gupta told BBCindicates an almost certain cure. While the solution isnt permanent for certain, it is a step in the right direction for the millions of people living with HIV.

3. People adopted more pets.

At this time, there is no evidence that pets can spread COVID-19. What does that mean for America? More adoption, apparently! Mans best friend comes in clutch yet again, providing endless entertainment for the millions of Americans feeling lonesome in their homes. However, not everyone is willing to take the plunge with a permanent pet pal in this time of economic uncertainty; according to The New York Times, the number of fostering requests across the United States have spiked in recent weeks. Not only is this benefitting the animals themselves whod otherwise be isolated in kennels, but it satiates the need for companionship that their new owners are craving. Reach out to your local Humane Society or Animal Care Center to learn more about how you can adopt or foster a pet in your area.

4. Italians went off.

If you havent seen the videos trending all over Twitter and Instagram, I dont know where youve been. Italians have been doing the most while under strict quarantine, taking their energy and flair to their balconies while singing hit singles karaoke-style. Theyve pulled out all the stops, even bringing out instruments to serenade each other across the streets. Time and time again, history has proven the strength of the unifying power of music in hardship, and this is no exception. The countrys death toll may surpass even Chinas, but that hasnt stopped Italians from trying to have a good time.

5. People actually started using Netflix Party.

Lets be honest, when you and your friends hang out, 5 percent of the time is spent going on spontaneous outings while the other 95 percent blows by while youre on the couch watching Netflix. With Netflix Party, a Chrome extension that synchronizes your Netflix screening, you can still host movie nights with virtually (pun intended) everyone. After downloading the extension from netflixparty.com, all you have to do is open Netflix in your browser, start watching your favorite show, and then click the NP on the upper-right corner of your screen. From there, a chat should pop up, providing you with a sharable link that you can send to all your friends. But wheres the virtual popcorn?

6. Google Arts and Culture allowed us to stroll through online museums.

Google Arts & Culture is what some would call the pioneer of virtual exploration, partnering with over 500 global art institutions to allow anyone with internet access to interact with the same enriching experience of a traditional museum from the comfort of their La-z-boy. The app officially launched in 2016, but the latest advancements in virtual reality provide a whole new platform to experience while youre bundled up at home. Whether you want to stroll through Versailles or make a pit-stop at the National Museum of Modern and Contemporary Art in Korea, the innovators at Google allow you to do it all.

7. Everyone got better at TikTok dances.

At this point in quarantine, youd be lying if you said you hadnt even tried to memorize a TikTok dance with all this time on your hands. Savage by Megan Thee Stallion (shoutout Commodore Quake) has gone viral on the popular app, with everyone from Tyler and Hannah (The Bachelorette lovebirds) to Megan Thee Stallion herself taking their shot at the trending dance. The hashtag #boredathome has also been flooding everyones TikTok For You page, featuring families and their various shenanigans while on lockdown. But seriously, why does everyone have a funny dad?

See original here:
March 21: 7 best things that happened this week - The Vanderbilt Hustler

Letters to the editor: Goose feces – News – Mount Shasta Herald

By Stem Cell Doctors

FridayMar20,2020at12:01AM

This letter is not intended to impugn the service, doctors or staff of Mercy Medical Hospital of Mount Shasta.

There is however an issue that I have tried to call attention to for the last 4 years. The geese. I am a stage 4 lymphoma cancer survivor, and a stem cell transplant recipient.

The issue is that the feces from the geese, its everywhere including the roof of the building. I know that the hospital has made a major effort to wash the sidewalks down. Not getting all the mess and not realizing that what was washed into the grass dries out and becomes airborne when disturbed.

You really must pay attention to where you walk because if you step in it and take it home on your shoes, it gets on your carpet or other surfaces and dries then can become airborne.

I happened by chance to speak with a hospital board member that admitted the hospital made a major mistake in putting in the pond at the hospital.

Having spent time in the UC Davis Medical System (not the cleanest), I hold Mercy Medical in Redding as the most biologically clean facility in northern California, Mount Shasta would be next if the pond and geese were gone.

Please dont ignore this issue. I would be glad to help find a solution.

Ken Roseberry

Mount Shasta

Follow this link:
Letters to the editor: Goose feces - News - Mount Shasta Herald

For Texas ill and immunocompromised, coronavirus brings a new threat and familiar precautions – KSAT San Antonio

By Stem Cell Doctors

After she stocked the deep freezer and canceled the physical therapy appointments, there still remained the problem of the mail.

At first, Shannon Huehlefeld would pick it up in a pair of hospital gloves she keeps a box by the door and thumb through it carefully. If she needed a letter immediately, shed spray it with Lysol on both sides. Everything else she just let sit. The virus, she knew, can live on some surfaces for days.

Shed been thinking about her vacuum, which has a light on its underside thats supposed to sterilize the floor beneath it. Then, last week, while she was shopping online for bacterial wipes, a solution appeared as a suggested purchase: a UVC bulb that can sterilize a surface in 30 minutes or less. She bought one she can screw into a clip-on lamp above the counter in the laundry room. Shell do one side, then flip the mail over and do the other.

Huehlefeld is not letting anyone in or out of the house near the Gulf Coast in Freeport that she shares with her husband, Ken, and their two Maltese mixes. That goes for the two of them and, unfortunately, for her niece, who after losing her mother in January had been coming over to see them a lot.

I said, Im sorry, Im so sorry, I miss you and I want to see you but I cannot let anybody get my husband sick, said Huehlefeld, 49. Spraying the mail I know it seems ridiculous. But I dont know where this [virus] stuff is, and they dont know where this stuff is. They dont even know who has it and where it is and where its not.

I cannot let my husband get sick, she continued, in something of a mantra. He doesnt know that he could survive a bad respiratory illness like that.

For Texans with compromised immune systems or those with sick loved ones the precautions being taken in the face of the new coronavirus are high stakes, and in some cases extreme. The limited scientific research about the mysterious COVID-19 shows it is deadliest for the elderly and the sick. Already, thousands have died worldwide and at least 69 people are infected in Texas.

But if only the immunocompromised are careful, the virus will continue to spread rapidly. Experts are exhorting even the young and healthy to limit social interaction in order to flatten the curve, slowing the rate of infection to ensure hospitals can care for all who fall ill. Cities across the county, including Dallas and Houston, have closed bars and banned dine-in service at restaurants in an effort to limit the spread of the virus. The Centers for Disease Control and Prevention recommended canceling any event of more than 50 people for the next eight weeks. But some in the most vulnerable population fear not everyone is taking the outbreak seriously enough.

Shannon Huehlefeld has rheumatoid arthritis, which means her immune system mistakenly attacks healthy cells in her body, causing severe fatigue and making it painful to move around. But she worries more about her husband, a retired sheriffs deputy, who is 63 and diabetic. In December 2014, he spent 10 days in intensive care with diabetic ketoacidosis, a serious complication of diabetes. He hasnt been the same since, she said; he lost the majority of his muscle mass, and hes very frail, with a history of lung issues and pneumonia. She still remembers the nurse scolding her for not bringing him in sooner.

She hasnt left the house since Super Tuesday two weeks ago, and when she did, she wiped down the car as best she could. They have at least a months supply of groceries; the deep freezer is so full it wont close. Worst-case scenario, shell ask her niece who is young and healthy and has been making a mint lately, working for a grocery delivery service to bring something by. Then shell get out her Lysol.

The coronavirus threat is new, but for many, the precautions are familiar. Its a collective-action conundrum that keeps the immunocompromised up at night. They are doing what they can. They just wish others would take the same steps.

We are perpetually at risk, said Shelby Chiles, 42, who along with her mother has neuro-Behcets, a rare autoimmune disease. Both wear nasal cannulas and rely on external oxygen supplies. Her husband works as a high school teacher in Frisco ISD essentially a petri dish, she said.

Its not really that different for me and my family on a day-to-day level, because we have to be cautious every day, she said. Its just the overwhelming response to how everyone else is being cautious. I wish that people used common sense and hygiene proper hygiene on a daily basis.

Renee Brown of Corinth is in her 50s, but she has what her doctor calls an immature immune system, like it was a child. Nineteen months after undergoing a stem cell transplant, she is no longer taking immunosuppressants, but she is still taking care. She has aplastic anemia, an autoimmune disease in which the bone marrow produces insufficient blood cells, and after her transplant, she spent weeks isolated in the hospital. She knows for her, the virus could be a problem.

But the virus doesnt frighten me, she said. Im not afraid of it because I know what to do. I have kind of had this lifestyle, of having to avoid the flu because I couldnt get vaccinated for it. Im actually pretty used to avoiding crowds when I can, washing my hands, that sort of thing.

Its other people she frets for more. She remembers from her months of isolation that some friends dont take illness seriously. They dont understand they need to stay away when theyre fighting a cough or running a fever. Theyre not cautious in public places. Some end up drifting away.

People dont understand, and they often dont comply, she said. They think about colds and flus in terms of things people get over.

For Tessa Phillips, who has had a weak immune system ever since she underwent a bone marrow transplant as a teenager, what might be a cold or bronchitis for a healthy person turns into walking pneumonia. Her ear infections turn into mastoiditis. She worries about what the new virus could do to her.

I dont think other people should be foolish about how they take care of themselves and impose that upon you, she said.

A year before the virus began to spread in Texas, she was already taking precautions to keep herself from getting sick when she had to travel for work. She drives instead of flying; she avoids hotels near airports; she skips restaurants and loathes gas stations.

But she knows others are not so careful. On Friday morning, the sound of a hacking cough from somewhere in her apartment complex sent her and her husband spinning.

Right now, it seems like its a very stark contrast: You either have doomsday preppers buying all the toilet paper, or youve got people who are just out and about like nothings happening, she said. All of us should be somewhere in that sweet spot in the middle. We all need to get in the middle together. But 6 feet away from each other.

There have not been any cases confirmed yet in Winnsboro, the rural East Texas town of about 3,300 where Bette Swann, 76, lives. But in Tyler, about 40 miles away, three people tested positive, the city announced Friday.

Thats getting really close to home, she said. Thats where my doctors are and where we go shopping.

When Swann goes to see her doctor in May, itll mark 14 years in remission from lung cancer. She was never a smoker, but she has half a lung missing, chronic obstructive pulmonary disease and asthma, as well as the autoimmune disease lupus. Her husband will be 80 next month.

So they are quarantining themselves at home, where she has already spent a not-insignificant portion of her time chastising Facebook friends who claim the virus is a hoax. When her sister called to remark on how few people were at Red Lobster for lunch Thursday, Swann scolded her, too: You shouldnt have been there, either.

Swann wasnt always so careful, even after cancer. She and her husband would leave the grocery store, and shed touch her face. He would scold her if she didnt use hand sanitizer first.

He really just kind of grounded me, she laughed. Id say, Dont tell me that! I can touch my nose if I want to.

But Im not doing that now, she said. I kind of learned.

Swann always gets the flu vaccine, but she still got the flu two of the last three years. Both times, it kept her bedridden for two weeks. One year, right before Christmas, the doctor told her she would need to be hospitalized if her fever didnt go down in 24 hours. She would have missed the holiday with her children. A day later, she felt well enough to go home.

She knows from her niece, an internist, that the threat of the coronavirus is far greater than that of the flu. She and her husband are up near that dangerous age. And she knows that her poor health makes her vulnerable.

Im in remission, but my immune systems not well. Evidently Im more prone to get sick, she said. Knowing how the flu affected her, she is scared about an illness that could hit her lungs even harder.

Swann and her husband dont much mind being home, where they stay most of the time anyway. They love to read. When it gets a little warmer, shell plant flowers in their garden. Her husband plants the peas.

They plan to call in grocery orders so they can get food delivered straight to the car. She doesnt miss eating out, but she does miss going to Walmart. And she hates that theyre not going to church.

Recently, Swann read a news story about a couple in Northern Italy who reportedly died of the virus within two hours of each other. Severa Belotti was 82, and Luigi Carrara was 86.

The story has stuck with her. They were just like my husband and I, active in their lives we go to church, we work in the garden, she said.

They had been isolated at home, and their son wasnt even able to see them before they died, she recalled. How sad that mustve been.

Original post:
For Texas ill and immunocompromised, coronavirus brings a new threat and familiar precautions - KSAT San Antonio

Disruptions in cancer care in the COVID-19 era – NewsDio

By Stem Cell Doctors

What your doctor is reading on Medscape.com:

MARCH 20, 2020 Even in the midst of the COVID-19 pandemic, cancer care must continue, but changes to the way care is provided may be necessary."We are heading toward a time when there will be significant disruptions in the care of cancer patients," said Len Lichtenfeld, MD, deputy chief medical officer for the American Cancer Society (ACS), in a statement. "For some it may be as simple as a delay in elective surgery. For others, it may be delaying preventive care or adjuvant chemotherapy to prevent cancer from coming back or rescheduling appointments."Lichtenfeld emphasized that cancer care teams will do their best to provide care to those most in need. However, even under those circumstances, life will not be as usual. "It will take patience from everyone as we go through this pandemic," he said."The way we treat cancer in the coming months will change enormously," writes a British oncologist in an article published in The Guardian."As oncologists, we will have to find a tenuous balance between insufficient treatment of people with cancer, leading to more deaths from the disease in the medium and long term and the increase in deaths from COVID-19 in a population of vulnerable patients. Together with our patients, we will have to make difficult decisions regarding treatments, with only low-quality evidence to guide us, "writes Lucy Gossage, MD, consulting oncologist at the University Hospital of Nottingham, UK.Evidence to date (from China's Lancet Oncology reports) suggests that people with cancer are at significantly higher risk of serious disease resulting in intensive care admissions or death when infected with COVID-19, particularly if they recently received chemotherapy or surgery."Many of the cancer treatments we use today, especially those given after surgery to reduce the risk of cancer recurrence, have relatively small benefits," he writes."In the current climate, the balance of offering these treatments may change; a small reduction in the risk of cancer recurrence in the next 5 years may be offset by the potential for a short-term increase in the risk of death from COVID- 19. In the long term, more people's cancer will come back if we can't offer these treatments, "he adds.

Continued

Postpone routine detection

One thing that may be in the background for now is the routine cancer screening, which can be postponed for now to conserve health system resources and reduce contact with health centers, ACS says."Patients seeking routine cancer screenings should delay them until further notice," said Lichtenfeld. "While early detection is important, the need to prevent the spread of the coronavirus and reduce strain on the medical system is more important at this time."But as soon as restrictions are lifted to reduce the spread of COVID-19 and routine visits to health facilities are safe, regular screenings should be rescheduled.

ASCO Orientation

The American Society for Clinical Oncology (ASCO) has released a new guide on caring for cancer patients during the COVID-19 outbreak.First, ASCO encourages providers, centers, and anyone caring for cancer patients to follow existing guidelines from the Center for Disease Control and Prevention (CDC) when possible.ASCO highlights the CDC's general recommendation for healthcare facilities that suggests that "elective surgeries" in inpatient facilities be rescheduled if possible, which has also been recommended by the American College of Surgeons.However, in many cases, cancer surgery is not elective but essential, he notes. Therefore, this is very much an individual determination that doctors and patients will need to make, considering the potential harm of delaying the cancer related surgery that is needed.Systemic treatments, including chemotherapy and immunotherapy, leave cancer patients vulnerable to infection, but ASCO says there is no direct evidence to support changes in regimens during the pandemic. Therefore, it is not recommended to routinely discontinue anticancer or immunosuppressive therapy, as the balance of potential harm that may result from delaying or stopping treatment versus the potential benefits of possibly preventing or delaying COVID-19 infection remains very unclear.Clinical decisions should be individualized, ASCO emphasized, and suggested that the following points of practice be considered:

For patients who are already in deep remission and who are receiving maintenance therapy, stopping treatment may be an option.

Some patients may switch from IV to oral therapies, which would decrease the frequency of clinic visits.

Decisions about modifying or discontinuing chemotherapy should take into account both the indication and the goals of care, as well as the patient's location in the treatment regimen and tolerance to therapy. As an example, the risk-benefit assessment for continuing chemotherapy in patients with untreated extensive small cell lung cancer is quite different from proceeding with pemetrexed maintenance for metastatic non-small cell lung cancer.

If local coronavirus transmission is a problem at a particular cancer center, reasonable options may include taking a 2-week break from treatment or scheduling treatment at a different center.

Assess whether the infusion at home is medically and logistically feasible.

In some settings, delaying or modifying adjuvant treatment presents a higher risk of compromised disease control and long-term survival than others, but in cases where the absolute benefit of adjuvant chemotherapy may be quite small and there are other options. available, the risk of COVID -19 can be considered an additional factor when evaluating care.

Continued

Delaying stem cell transplants

For patients who are candidates for allogeneic stem cell transplantation, a delay may be reasonable if the patient is currently well controlled with conventional treatment, ASCO says. It also directs physicians to follow the recommendations provided by the American Society for Transplantation and Cell Therapy and by the European Society for Blood and Marrow Transplantation regarding this matter.Finally, there is also the question of prophylactic antiviral therapy: should it be considered for cancer patients undergoing active therapy?The answer to that question is currently unknown, ASCO says, but "this is an active area of research and the evidence may be available at any time."

Medscape Medical News

2020 WebMD, LLC. All rights reserved.. (tagsToTranslate) cancer (t) malignancy (t) carcinoma (t) Coronavirus (t) 2019 New coronavirus (t) 2019-nCoV (t) Wuhan coronavirus (t) Human coronavirus HKU1 (t) Human coronavirus OC43 (t) HCoV -OC43 (t) Human coronavirus 229E (t) HCoV-229E (t) chemotherapy (t) biological therapy (t) immunotherapy (t) cancer risk (t) pandemic (t) transplant (bone marrow) (t) bone marrow transplant (t) bone marrow (transplant) (t) bmt (t) hematology (t) patient safety

View original post here:
Disruptions in cancer care in the COVID-19 era - NewsDio

→←